Our Mission

The Longevity Biotechnology Association is a global non-profit organization, composed of a network of longevity biotech companies, pharmaceuticals,  researchers, and investors. Our mission is to set industry standards, educate stakeholders and collaborate to translate geroscience to prevent the diseases associated with aging and extend health span.

Our Vision

LBA envisions a world where health regulatory bodies recognize that aging is the primary driver for most diseases (geroscience). Accordingly, the LBA would like the currently identified aging pathways to be targeted by recognized therapeutic solutions. Gerotherapeutics need to be recognized as beneficial to society and should be made available to all of humanity.

Human life expectancy has nearly doubled since 1900 thanks to medicine's
immense progress against
infectious diseases.

However, a consequence is that the diseases of aging have replaced infectious diseases as humanity's leading cause of death.

After decades of failure to eliminate any major age-related disease, new insights into the way the human body changes as we age have led to unprecedented optimism concerning foreseeable treatment for today's most pressing conditions.

Geroscientists have devised hundreds of interventions that can extend the healthy lifespan of animals in laboratory studies.

These interventions have now started to leave the lab bench and make their way into the clinic, shepherded by a diverse group of scientists, physicians, drug developers, businesspeople, investors, and patients.

It’s therefore timely that the leading stakeholders in this emerging sector have come together to form the
Longevity Biotechnology Association, with the following goals:

Define and Set


To distinguish between non-science-backed spurious longevity claims and scientifically designed studies to lay the framework for translating geroscience


To provide insightful advice to those new to this field about fundamental approaches and processes

Work with


To work with partners to establish well-defined, rapid regulatory paths to approval that will bring this new class of therapies to patients.


To educate stakeholders (investors, governments, the medical industry, the media, and the public )about the promise of emerging therapies with the potential to treat or prevent multiple age-related conditions at once.


To collaborate to translate geroscience and create and disseminate best practices in the geroscience field.